Canada Markets open in 1 hr 57 mins

iCo Therapeutics Inc. (ICO.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.10500.0000 (0.00%)
At close: 3:59PM EDT
Full screen
Previous Close0.1050
Open0.1050
Bid0.1000 x 0
Ask0.1000 x 0
Day's Range0.1000 - 0.1100
52 Week Range0.0300 - 0.1600
Volume1,309,660
Avg. Volume2,758,588
Market Cap18.273M
Beta (5Y Monthly)2.73
PE Ratio (TTM)N/A
EPS (TTM)-0.0120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • IIROC Trading Halt - ICO
    CNW Group

    IIROC Trading Halt - ICO

    VANCOUVER, BC, March 22, 2021 /CNW/ - The following issues have been halted by IIROC: Company: iCo Therapeutics Inc.TSX-Venture Symbol: ICO All Issues: YesReason: At the Request of the Company Pending NewsHalt Time (ET): 7:46 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.

  • Newsfile

    iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.

    Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo") and Satellos Bioscience Inc. ("Satellos"), a private Canadian corporation, together are pleased to announce the execution of a definitive agreement, dated March 21, 2021 (the "Arrangement Agreement"), providing for the business combination of iCo and Satellos by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business Corporations Act (the ...

  • iCo Therapeutics, Inc. Announces Agreement for in Vivo Testing of iCo-019 on SARS-CoV-2
    Newsfile

    iCo Therapeutics, Inc. Announces Agreement for in Vivo Testing of iCo-019 on SARS-CoV-2

    Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced that its wholly owned subsidiary, Amphotericin B Technologies, Inc., has entered into an agreement with IIT Research Institute to test the in vivo efficacy of iCo's novel oral amphotericin B asset ("iCo-019") against SARS-CoV-2, the causative agent of COVID-19 in the hACE2 mouse model (the "iCo-019 Study"). iCo anticipates that the iCo-019 ...